<DOC>
	<DOCNO>NCT02630680</DOCNO>
	<brief_summary>The purpose study assess Eziclen/Izinova drug utilisation real life set representative sample European target population .</brief_summary>
	<brief_title>Eziclen Drug Utilisation Real Life Setting</brief_title>
	<detailed_description />
	<criteria>Patient eligible prescription BLI800 ( Eziclen®/Izinova® ) cleanse bowel preparation accordance marketing authorisation . Patient provide write informed consent . Patient eligible prescription BLI800 ( Eziclen®/Izinova® ) cleanse bowel preparation accordance marketing authorisation . Specifically , patient contraindication use product , include patient congestive heart failure , severe renal insufficiency active inflammatory bowel disease , eligible inclusion study . Patient prescribe cleanse bowel preparation BLI800 ( Eziclen®/Izinova® ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>